|
1
|
Duruisseaux M, Besse B, Cadranel J, Pérol
M, Mennecier B, Bigay-Game L, Descourt R, Dansin E,
Audigier-Valette C, Moreau L, et al: Overall survival with
crizotinib and next generation ALK-inhibitors in ALK-positive
non-small-cell lung cancer (IFCT-1302 CLINAKL): A French nationwide
cohort retrospective study. Oncotarget. 8:21903–21917. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Planchard D, Smit EF, Groen HJM, Mazieres
J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P,
Mookerjee B and Johnson BE: Dabrafenib plus trametinib in patients
with previously untreated BRAF V600E-mutant metastatic
non-small-cell lung cancer: An open-label, phase 2 trial. Lancet
Oncol. 18:1307–1316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib
versus gefitinib as first-line treatment for patients with
EGFR-mutation positive non-small-cell lung cancer (ARCHER 1050): A
randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaw AT, Ou SH, Bang YJ, Camidge DR,
Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa
DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung
cancer. N Engl J Med. 371:1963–1971. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shea M, Costa DB and Rangachari D:
Management of advanced non-small cell lung cancers with known
mutations or rearrangements: Latest evidence and treatment
approaches. Ther Adv Respir Dis. 10:113–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus Chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kupferman ME, Jiffar T, El-Naggar A,
Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D and
Myers JN: TrkB induces EMT and has a key role in invasion of head
and neck squamous cell carcinoma. Oncogene. 29:2047–2059. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burdsal CA, Damsky CH and Pedersen RA: The
role of E-cadherin and integrins in mesoderm differentiation and
migration at the mammalian primitive streak. Development.
118:829–844. 1993.PubMed/NCBI
|
|
9
|
Lee YC, Wu CT, Chen CS and Chang YL:
E-cadherin expression in surgically-resected non-small cell lung
cancers-a clinicopathological study. Thorac Cardiovasc Surg.
48:294–299. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kase S, Sugio K, Yamazaki K, Okamoto T,
Yano T and Sugimachi K: Expression of E-cadherin and ß-catenin in
human non-small cell lung cancer and the clinical significance.
Clin Cancer Res. 6:4789–4796. 2000.PubMed/NCBI
|
|
11
|
Choi YS, Shim YM, Kim SH, Son DS, Lee HS,
Kim GY, Han J and Kim J: Prognostic significance of E-cadherin and
ß-catenin in resected stage I non-small cell lung cancer. Eur J
Cardiothorac Surg. 24:441–449. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Richardon F, Young GD, Sennello R, Wolf J,
Argast GM, Mercado P, Davies A, Epstein PM and Wacker B: The
evaluation of E-cadherin and vimentin as biomarkers of clinical
outcomes among patients with non-small cell lung cancer treated
with erlotinib as second- and third-line therapy. Anticancer Res.
32:537–552. 2012.PubMed/NCBI
|
|
13
|
Soltermann A, Tischler V, Arbogast S,
Braun J, Probst-Hensch N, Weder W, Moch H and Kristiansen G:
Prognostic significance of epithelial-mesenchymal and
mesenchymal-epithelial transition protein expression in non-small
cell lung cancer. Clin Cancer Res. 14:7430–7437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Liu J, Yue D, Gao L, Wang D,
Zhang H and Wang C: Clinical significance or E-cadherin, ß-catenin,
vimentin and S100A4 expression in completely resected squamous cell
lung carcinoma. J Clin Pathol. 66:937–945. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Voon DC, Huang RY, Jackson RA and Thiery
JP: The EMT spectrum and therapeutic opportunities. Mol Oncol.
11:878–891. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Terry S, Savagner P, Ortiz-Cuaran S,
Mahjoubi L, Saintigny P, Thierry JP and Chouaib S: New insights
into the role of EMT in tumor immune escape. Mol Oncol. 11:824–846.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gark AD, Dudek-Peric A, Romanio E and
Agostinis P: Immunogenic cell death. Int J Dev Biol. 59:131–140.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sato M, Shames DS and Hasegawa Y: Emerging
evidence of epithelial-to-mesenchymal transition in lung
carcinogenesis. Respirology. 17:1048–1059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhihua Y, Zhang X, Luo Y, Li S, Huang L,
Li Z, Li P and Chen G: Prognostic values of vimentin expression and
its clinicopathological significance in non-small cell lung cancer:
A meta-analysis of observational studies with 4118 cases. PLoS One.
11:e01631622016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dauphin M, Barbe C, Lemaire S,
Nawrocki-Raby B, Lagonotte E, Delepine G, Birembaut P, Gilles C and
Polette M: Vimentin expression predicts the occurrence of
metastases in non small cell lung carcinomas. Lung Cancer.
81:117–122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sui H, Zhu L, Deng W and Li Q:
Epithelial-mesenchymal transition and drug resistance: Role,
molecular mechanisms and therapeutic strategies. Oncol Res Treat.
37:584–589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yauch RL, Januario T, Eberhard DA, Cavet
G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, et al:
Epithelial versus mesenchymal phenotype determines in vitro
sensitivity and predicts clinical activity of erlotinib in lung
cancer patients. Clin Cancer Res. 11:8686–8698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Witta SE, Gemmill RM, Hirsch FR, Coldren
CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita
M, et al: Restoring E-cadherin expression increases sensitivity to
epidermal growth factor receptor inhibitors in lung cancer cell
lines. Cancer Res. 66:944–950. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thomas M, Fischer J, Andreas S, Kortsik C,
Grah C, Serke M, von Eiff M, Witt C, Kollmeier J, Müller E, et al:
Erlotinib and bevacizumab versus cisplatin, gemcitabine and
bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
Eur Respir J. 46:219–229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu Y, Liu H, Ding M, Liu J, Zhan P, Fu X
and Gan L: The impact of E-cadherin expression on non-small cell
lung cancer survival: A meta-analysis. Mol Biol Rep. 39:9621–9628.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren S, Su C, Wang Z, Li J, Fan L, Li B, Li
X, Zhao C, Wu C, Hou L, et al: Epithelial phenotype as a predictive
marker for response to EGFR-TKIs in non-small cell lung cancer
patients with wild-type EGFR. Int J Cancer. 135:2962–2971. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nikolova DA, Asangani IA, Nelson LD,
Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR,
Manegold C and Allgayer H: Cetuximab attenuates metastasis and
u-PAR expression in non-small cell lung cancer: u-PAR and
E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer
Res. 69:2461–2470. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Herbst RS, Ansari R, Bustin F, Flynn P,
Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P and Hainsworth
J: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in
advanced non-small-cell lung cancer after failure of standard
first-line chemotherapy (BeTa): A double-blind, placebo-controlled,
phase 3 trial. Lancet. 377:1846–1854. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Seto T, Kato T, Nishio M, Goto K, Atagi S,
Hosorni Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al:
Erlotinib alone or with bevacizumab as first-line therapy in
patients with advanced non-squamous non-small-cell lung cancer
harbouring EGFR mutations (JO25567): An open-label, randomized,
mutlicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rosell R, Dafni U, Felip E,
Curioni-Fontecedro A, Gautschi O, Peters S, Massuti B, Palmero R,
Aix SP, Carcereny E, et al: Erlotinib and bevacizumab in patients
with advanced non-small-cell lung cancer and activating EGFR
mutations (BELIEF): An international, multicentre, single-arm,
phase 2 trial. Lancet Respir Med. 5:435–444. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Prudkin L, Liu DD, Ozburn NC, Sun M,
Behrens C, Tang X, Brown KC, Bekele BN, Moran C and Wistuba II:
Epithelial-to-mesenchymal transition in the development and
progression of adenocarcinoma and squamous cell carcinoma of the
lung. Mod Pathol. 22:668–678. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garassino MC, Martelli O, Broggini M,
Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F,
Moscetti L, et al: Erlotinib versus docetaxel as second-line
treatment of patients with advanced non-small-cell lung cancer and
wild-type EGFR tumours (TAILOR): A randomized controlled trial.
Lancet Oncol. 14:981–988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garon EB, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel
J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel
for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): A
multicentre, double-blind, randomized phase 3 trial. Lancet.
384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reck M, Kaiser R, Mellemgaard A, Douillard
JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I,
Liao M, et al: Docetaxel plus nintedanib versus docetaxel plus
placebo in patients with previously treated non-small-cell lung
cancer (LUME-Lung 1): A phase 3, double-blind, randomized
controlled trial. Lancet Oncol. 15:143–155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fantozzi A, Gruber DC, Pisarsky L, Heck C,
Kunita A, Yilmaz M, Meyer-Schaller N, Cornille K, Hopfer U,
Bentires-Alj M and Christofori G: VEGF-mediated angiogenesis links
EMT-induced cancer stemness to tumor initiation. Cancer Res.
74:1566–1575. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yi ZY, Feng LJ, Xiang Z and Yao H:
Vascular endothelial growth factor receptor-1 activation mediates
epithelial to mesenchymal transition in hepatocellular carcinoma
cells. J Invest Surg. 24:67–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Y, Yang X, Su LJ and Flaig TW: VEGFR
and EGFR inhibition increases epithelial cellular characteristics
and chemotherapy sensitivity in mesenchymal bladder cancer cell.
Oncol Rep. 24:1019–1028. 2010.PubMed/NCBI
|
